Amgen Inc. company was founded in 1980 and is based in Thousand Oaks, California. Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada.

LipoScience, Inc. company was founded in 1994 by its chief scientific officer, Dr. James Otvos. LipoScience, Inc. company's primary product, the NMR LipoProfile, uses nuclear magnetic resonance (NMR) therapy to analyze blood samples and assess the levels of lipoprotein particles in the bloodstream. (Such particles contain cholesterol, and detection of them can help pinpoint cardiovascular risks.) The LipoProfile differs from other cholesterol tests in that it does not require physical separation of the particles. LipoScience markets the LipoProfile and other traditional diagnostic tests through a direct sales force to health care providers and research labs.

MaxCyte will put your blood cells to work. Its cell loading technology uses blood cells instead of viral vectors to transport gene therapies to target sites, increasing their safety and efficacy. The company partners with drug makers to help them develop more effective therapies in a shorter amount of time. Partners include AlphaVax, Sangamo BioSciences, and United Therapeutics. MaxCyte is also working on its own therapies, including potential treatments for chronic lymphocytic leukemia, lymphoma, and breast and ovarian cancer. CEO Douglas Doerfler and other backers control the company after EntreMed spun it off.

Nycomed International Management GmbH the Swiss pharmaceutical company develops presciption and OTC medicines mainly focusing on cardiology, gastroenterology, osteoporosis, respiratory, and pain management therapies. It operates nearly 20 facilities in a dozen European countries, where it conducts its own research and drug testing. It also develops products in conjunction with partner pharmaceutical companies. The majority of Nycomed's revenues come from direct drug sales to doctors, hospitals, and pharmacies in Europe, the Americas, Russia, and Asia/Pacific as well as from licensing product rights to and from other companies.

Mymetics Corporation is a biotechnology research and development company focused on fundamental and applied research in the area of human biology and medicine. Mymetics's primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus (HIV), the virus that leads to acquired immunodeficiency syndrome (AIDS). Mymetics has also acquired from a scientific partner an advanced malaria vaccine project, which is in phase II clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for malaria, human oncoviral leukemias, multiple sclerosis and organ transplantation. In April 2009, the Company completed the acquisition of Bestewil Holding B.V. and its subsidiary, Virosome Biologicals B.V., from Norwood Immunology Limited.

Since its founding in 1928, the Hannah Research Institute has conducted research aimed at making food healthier and safer. The institute, which has links to the University of Glasgow and the Scottish Agricultural College, receives funding from the Scottish Government, medical charities, and pharmaceutical companies. Its Biomedical division conducts research on the links between health and nutrition, while the CHARIS Food Research division ... researches food. In particular, the Institute seeks to understand how environment, physiology, genetics, and other factors affect susceptibility to breast cancer, cardiovascular disease, diabetes, and obesity.

Avacta will take a closer look and get back with you. The biophysics company makes its money from the exact science of detecting molecules. Its Avacta Analysis arm provides analytical and research services to the pharmaceutical, healthcare, and personal care industries. It also offers expert witness services to assist in pharmaceutical patent disputes and suspected counterfeiting cases. The company's technology arm has developed a product to help drug developers analyze and predict the potential usefulness of biological drug compounds. The company also owns veterinary laboratory services provider YorkTest Veterinary Services, and diagnostic test maker Curidium Medica.

FAES was founded in 1933. Faes Farma SA is a Spanish company primarily engaged in the research, manufacture and commercialization of pharmaceutical products, such as prescription drugs, over-the-counter medicines and skin-care treatments, as well as raw materials used in the pharmaceutical industry. The Company’s facilities include one research and development center and three manufacturing plants, which are located in the cities of Leioa, Lisbon and Madrid. The Company is a parent of Grupo Faes, a group which comprises Laboratorios Vitoria SA, Laboratorios Veris SA, Iquinosa Farma SA, Lazlo International SA, Hispana Dos SA SICAV, Ingaso Farm SLU, Biotecnet I MAS D SA, Esfion SA, Olve Farmaceutica Lda, Veris Farmaceutica Lda, Vitalion Lda and Farmalavi Lda. Through its subsidiaries, the Company operates mainly in Spain and Portugal. It also has presence in approximately 50 countries in Europe, America, Africa and Asia.

Applied Genetic Technologies Corporation company was formed in 1999; funding partners include InterWest Partners, InterSouth Partners, and MedImmune Ventures. Applied Genetic Technologies Corporation (AGTC) applies itself to developing gene therapies for acquired and inherited genetic diseases. Its lead product is a treatment for Alpha One Antitrypsin Deficiency, which is an inherited cause of emphysema that is the most common hereditary disease in the Western World. Aside from causing lung disease in adults, it can also lead to liver disease in children. AGTC is also developing a treatment for Leber Congenital Amaurosis, which causes blindness, in collaboration with the universities of Florida and Pennsylvania, and Cornell University.

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.